Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)
Year: 2026
Type: article
Study design: Observational Study
Abstract: PURPOSE: To evaluate the real-world impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on health-related quality of life (HRQoL) and metabolic outcomes in adults with type 2 diabetes and obesity. METHODS: We conducted a multicenter prospective cohort study across 13 primary-care centers in Spain. Adults with type 2 diabetes and body mass index (BMI) > 30 kg/m² initiating a GLP-1 RA were followed for 44 weeks. Baseline and week-44 assessments included anthropometric and biochemical parameters and HRQoL measured using the EQ-5D index and visual analogue scale (VAS), and the SF-12 physical and mental component summaries (PCS/MCS). Changes were analyzed using paired statistical tests overall and by achievement of ≥5% weight loss. FINDINGS: Among 135 patients, significant improvements were observed in glucose, HbA1c, LDL-C, waist circumference, body weight, and BMI. HRQoL improved in EQ-5D domains including mobility, pain/discomfort, and anxiety/depression. The EQ-5D index increased from 0.71 to 0.79 (P < 0.001), and VAS from 58.3 to 65.3 (P = 0.007). SF-12 PCS improved significantly, whereas MCS showed no overall change. Patients achieving ≥5% weight loss experienced greater improvements in EQ-5D index, VAS, and PCS. Subcutaneous and oral semaglutide improved the EQ-5D index; oral semaglutide improved VAS and MCS; and subcutaneous semaglutide improved PCS. IMPLICATIONS: In routine clinical practice, GLP-1 RAs were associated with clinically meaningful improvements in HRQoL and metabolic outcomes, particularly when ≥5% weight loss is achieved, supporting the integration of patient-reported outcomes into diabetes and obesity management. TRIAL REGISTRATION CLINICALTRIALS. GOV IDENTIFIER: NCT05136287.
Source: Clinical Therapeutics
Authors: José Seijas-Amigo, Ángel Salgado-Barreira, Carlota Roca-Martinez, Rosana Castelo-Dominguez, María Teresa Pérez-Álvarez, Belén Ponce-Piñón, Marlén Fernández-Silva, Marta Rodríguez-Barreiro, Mercedes Pereira-Pía, Jose Manuel Iglesias-Moreno, Mar Gago-García, Raquel Montáns-García, Agustina Fernandez-Perez, Dolores Fraga-Gayoso, Montse Fernandez-Montenegro, Beatriz Riveiro-Barciela, Natalia Rilla-Villar, Begoña Cardeso-Paredes, Marta Ribeiro-Ferreiro, Diego Rodriguez-Penas, Alberto Cordero, Moisés Rodríguez-Mañero, José R González-Juanatey
Institutions: Universidade de Santiago de Compostela, Centro de Investigación en Red en Enfermedades Cardiovasculares, Centro de Investigación Biomédica en Red, Instituto de Investigación Sanitaria de Santiago, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Universitat de Miguel Hernández d'Elx, Complejo Hospitalario Universitario de Santiago
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,240
OpenAlex ID: W7160545543